Editas Medicine – Hot or Not

Editas Medicine (Nasdaq:EDIT) is a genome editing company which owns the main CRISPR Cas9 patents. It has a market cap of $692.7 million, but makes no profits and pays no dividends. Guest Joseph Busha from JM BUSHA Investment Group and resident expert Paul Theron from Vestact decide whether Editas Medicine is hot or not.

Leave a Comment